News & Developments
ViewView
Press Releases

AKD strengthens Luxembourg litigation practice with the arrival of Eric Perru

AKD continues to strengthen its presence across key disciplines. The latest step in this momentum is the arrival of Eric Perru, who joins as partner in our Luxembourg litigation practice effective 1 October. Eric brings extensive experience in civil and commercial disputes, with a focus on financial services litigation. As a member of the Civil Procedure Commission of the Luxembourg, Eric contributed to the draft Bill that will soon introduce class actions into Luxembourg law. This places him — and AKD — at the forefront of a major shift in the market. He is particularly active in disputes in the financial services sector, including consumer, regulatory, ESG and liability. “With the digitalisation of justice, the development of artificial intelligence in dispute resolution and the imminent adoption of class action law in Luxembourg, litigation is entering a new era,” says Eric. “AKD combines Benelux reach with recognised expertise in class actions in the Netherlands. That is why I have joined — to deliver clients highly effective defence, both in advisory and in litigation.” Eric’s style is pragmatic and driven. Guided by the mantra Focus – Efficiency – Action, he treats disputes as strategic risks. His approach is to reduce uncertainty, protect value and create clear pathways to the best possible outcome — whether in court or in settlement negotiations. “Disputes are an unavoidable part of doing business, but how they are managed makes all the difference,” Eric adds. “My goal is to cut through complexity and deliver clarity.” “We are consistently broadening our capabilities in areas that are critical to our clients’ success,” says Carlos Pita Cao, managing partner of AKD. “With strong expertise in litigation in the Netherlands and Belgium, and now Eric joining to lead the team in Luxembourg, AKD is uniquely positioned as the Benelux firm that combines local insight and knowledge with cross-border strength.” With Eric on board, AKD underlines its position as the Benelux firm to watch - growing with pace, investing in talent, and expanding consistently across the disciplines that define the future of business.
AKD - October 14 2025
Press Releases

GSK Stockmann advises Merz Objektbau on sale of residential development in Heidenheim to VALUES Real Estate

GSK Stockmann provided ongoing advice to Merz Objektbau GmbH throughout the project, as well as on the sale by way of a forward deal of a residential development already under construction on Kleebühlweg in Heidenheim-Nord. The buyer, VALUES Real Estate, intends to incorporate the project into the newly launched “VALUES Impact Living” fund for subsidised housing (special AIF in accordance with Art. 9 SFDR). The new residential quarter will comprise around 4,380 sqm of rental space, containing a total of 61 one- to five-room flats and the corresponding number of parking spaces. Completion is scheduled for the second quarter of 2026. The project will be constructed using a serial timber hybrid method and has been designed to meet the KfW 40 energy efficiency standard. All flats will be wheelchair accessible and have balconies or terraces and fitted kitchens. The focus is on providing housing for middle-class tenants who are eligible for subsidised housing (WBS). The starting rent is EUR 8.50 per square metre, around 40% below the comparative rent for the local area. VALUES Real Estate plans to integrate the project into its ESG-focused investment strategy, which prioritises projects with a strong social and environmental impact. Advisers of Merz Objektbau at GSK Stockmann: Dr Olaf Schmechel (lead, Real Estate Investments & Asset Management), Çağlayan Birkan (Real Estate Investments & Asset Management), Frank-Florian Seifert (Public Law), Dr Oda Wedemeyer (Construction Law), Rebecca Comtesse (Financing/Subsidies) GSK Stockmann is a leading independent European corporate law firm. Over 250 professionals advise German and international clients at our locations in Berlin, Frankfurt/M., Hamburg, Heidelberg, Munich, Luxembourg and London. GSK is the law firm of choice for Real Estate and Financial Services. We also have deep-rooted expertise in key sectors including Funds, Capital Markets, Public, Mobility, Energy and Healthcare. For international transactions and projects, we work together with selected reputable law firms abroad. Our advice combines an economic focus with entrepreneurial foresight. That is what is behind: Your perspective. More about us: www.gsk.de [caption id="attachment_52618" align="alignnone" width="300"] GSK Berlin[/caption]
GSK Stockmann - October 14 2025
Press Releases

GSK Stockmann advises GIEAG on financing of residential construction project in Karlsruhe

GSK Stockmann advised GIEAG Immobilien AG on the financing for the construction of 218 new apartments in Karlsruhe via an international consortium of investors led by Crestline Investors, Inc. and Tite Street Capital. GIEAG Immobilien AG is moving ahead with the KWARTIER HOMES residential project in Karlsruhe’s Südstadt district. Comprising 218 apartments, expansive outdoor spaces, and three basement levels, including two for underground parking, KWARTIER HOMES is one of the most significant residential construction projects in the region. A GSK Stockmann team led by Munich partner Mechtild-Maria Siebke advised GIEAG on the project financing. Crestline Investors, together with its investment partner Tite Street Capital, secured full financing for the project via an international consortium of investors. Crestline Investors is a global institutional investment company with total assets under management of around USD 18 billion. Financial service provider Prime Capital also advised GIEAG in connection with the financing. Advisers of GIEAG Immobilien AG at GSK Stockmann: Dr Mechtild-Maria Siebke (lead, Finance), Andreas Dimmling (Corporate/Restructuring), Stephan Wachsmuth, Dominik Berka (both Tax); Associates: Marcel Alexander Buss (Finance), Theodor Lammich (Corporate/Restructuring). Contact: GSK STOCKMANN Dr Mechtild-Maria Siebke Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174 - 667 F +49 89 288174-44 [email protected] Press contact: GSK STOCKMANN Christina Holl Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174-275 F +49 89 288 174-44 [email protected] GSK Stockmann is a leading independent European corporate law firm. Over 250 professionals advise German and international clients at our locations in Berlin, Frankfurt/M., Hamburg, Heidelberg, Munich, Luxembourg and London. GSK is the law firm of choice for Real Estate and Financial Services. We also have deep-rooted expertise in key sectors including Funds, Capital Markets, Public, Mobility, Energy and Healthcare. For international transactions and projects, we work together with selected reputable law firms abroad. Our advice combines an economic focus with entrepreneurial foresight. That is what is behind:  Your perspective. More about us: www.gsk.de
GSK Stockmann - October 10 2025
Press Releases

GSK Stockmann advises Art-Invest Real Estate on sale of Momenturm in Munich’s Werksviertel district

GSK Stockmann advised Art-Invest Real Estate on the sale of the Momenturm office building, located in Munich’s Werksviertel district, to Generali. The European commercial law firm has provided ongoing support to Art-Invest Real Estate with the project since the initial acquisition of the property. Art-Invest Real Estate has sold the Momenturm project to Generali Deutschland. The transaction was carried out by Generali Real Estate S.p.A. on behalf of Generali Deutschland. The existing approx. 11,000 sqm of office space in the building, located at Rosenheimer Strasse 139, just a stone’s throw away from Munich Ostbahnhof, is to be extended to around 28,000 sqm. Generali Deutschland plans to use the building as its new corporate headquarters, with 1,500 employees expected to be relocated there. A GSK Stockmann team led by Munich-based partner Dirk Brückner has been providing Art-Invest Real Estate with comprehensive support on this project since it first acquired the property back in 2019. The firm’s advice encompassed project structuring, project development and securing planning permission, as well as the sale to Generali. Art-Invest Real Estate is a long-standing client of GSK Stockmann. Most recently, the law firm advised the company on the acquisition of a hotel portfolio in 2024, which included properties in Berlin, Oberhausen, Koblenz and Frechen near Cologne. Other past projects include the acquisition of the Wangen office campus in Stuttgart and the Arnulfbogen in Munich, both in 2021, as well as the commercial property F150 on the Frankfurter Ring in Munich and the City-Passage in Wiesbaden, both in 2022. Advisers of Art-Invest Real Estate at GSK Stockmann: Dr Dirk Brückner (lead), Dr Mark Butt (both Real Estate Transactions & Investments), Stefan Dorn (Project Development), Stefan Wachsmuth (Tax), Katharina Feierabend (Real Estate Transactions & Investments); Associates: Sebastian Gerhards (Tax), Maximiliane Bartsch, Melanie Patrizia Seitz (both Real Estate Transactions & Investments), Leonie Lindenbuß (Project Development) GSK München Contact: GSK STOCKMANN Dr Dirk Brückner Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174 - 71 F +49 89 288174-44 [email protected] Press contact: GSK STOCKMANN Christina Holl Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174-275 F +49 89 288 174-44 [email protected]   GSK Stockmann is a leading independent European corporate law firm. Over 250 professionals advise German and international clients at our locations in Berlin, Frankfurt/M., Hamburg, Heidelberg, Munich, Luxembourg and London. GSK is the law firm of choice for Real Estate and Financial Services. We also have deep-rooted expertise in key sectors including Funds, Capital Markets, Public, Mobility, Energy and Healthcare. For international transactions and projects, we work together with selected reputable law firms abroad. Our advice combines an economic focus with entrepreneurial foresight. That is what is behind:  Your perspective. More about us: www.gsk.de  
GSK Stockmann - September 17 2025